Literature DB >> 9006982

A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues.

J P Corradi1, C Yang, J C Darnell, J Dalmau, R B Darnell.   

Abstract

Paraneoplastic cerebellar degeneration (PCD) is believed to be an autoimmune disorder initiated by the ectopic expression of a neuron-specific protein in breast and ovarian tumors. PCD antisera was used previously to identify several cerebellar degeneration-related (cdr) genes encoding putative PCD antigens. We have found that the cdr2 gene, which encodes a cytoplasmic leucine zipper protein of unknown function, is expressed in PCD-associated tumors, whereas other cdr genes are not; thus, cdr2 encodes the PCD tumor antigen. To determine whether the expression pattern of cdr2 is consistent with its proposed role in PCD, we have isolated the mouse homolog and examined both the mRNA and protein distribution in adult tissues. We have found that cdr2 mRNA is expressed in almost all tissues, whereas the protein is expressed only in the brain and testis. Within the brain, both the cdr2 mRNA and immunoreactivity are confined primarily to neurons in the cerebellum and brainstem, the regions most affected in PCD. These results suggest first that the tissue-specific expression of cdr2 is regulated at a post-transcriptional level. Moreover, because the brain and testis are considered to be immune-privileged sites, the expression pattern of cdr2 is compatible with the autoimmune model of PCD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006982      PMCID: PMC6793730     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  40 in total

1.  The blood-brain barrier protects foreign antigens in the brain from immune attack.

Authors:  I F Pollack; R D Lund
Journal:  Exp Neurol       Date:  1990-05       Impact factor: 5.330

2.  HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal.

Authors:  A Szabo; J Dalmau; G Manley; M Rosenfeld; E Wong; J Henson; J B Posner; H M Furneaux
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

3.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

4.  A role for CD95 ligand in preventing graft rejection.

Authors:  D Bellgrau; D Gold; H Selawry; J Moore; A Franzusoff; R C Duke
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

5.  cis-acting elements in the 5'-untranslated region of rat testis proenkephalin mRNA regulate translation of the precursor protein.

Authors:  S M Rao; R D Howells
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

Review 6.  The structure and function of the blood-brain barrier.

Authors:  M W Bradbury
Journal:  Fed Proc       Date:  1984-02

7.  Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.

Authors:  F A Luque; H M Furneaux; R Ferziger; M K Rosenblum; S H Wray; S C Schold; M J Glantz; K A Jaeckle; H Biran; M Lesser
Journal:  Ann Neurol       Date:  1991-03       Impact factor: 10.422

8.  Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer.

Authors:  N E Anderson; M K Rosenblum; F Graus; R G Wiley; J B Posner
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

9.  Analysis of autoantibody binding to 52-kd paraneoplastic cerebellar degeneration-associated antigen expressed in recombinant proteins.

Authors:  K Sakai; T Ogasawara; G Hirose; K A Jaeckle; J E Greenlee
Journal:  Ann Neurol       Date:  1993-04       Impact factor: 10.422

10.  Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies.

Authors:  R B Darnell; L M DeAngelis
Journal:  Lancet       Date:  1993-01-02       Impact factor: 79.321

View more
  18 in total

1.  Unusual MRI abnormalities in anti-Yo positive "pure" paraneoplastic cerebellar degeneration.

Authors:  John C McHugh; Niall Tubridy; Conor D Collins; Michael Hutchinson
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

2.  The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.

Authors:  H J Okano; W Y Park; J P Corradi; R B Darnell
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

3.  Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.

Authors:  Iñigo Rojas-Marcos; Geraldine Picard; David Chinchón; Ellen Gelpi; Dimitri Psimaras; Bruno Giometto; J Y Delattre; J Honnorat; F Graus
Journal:  Neuro Oncol       Date:  2012-02-20       Impact factor: 12.300

4.  The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.

Authors:  Kevin J O'Donovan; Jennifer Diedler; Graeme C Couture; John J Fak; Robert B Darnell
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

5.  The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia.

Authors:  Y Y Yang; G L Yin; R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

6.  A hierarchy of Hu RNA binding proteins in developing and adult neurons.

Authors:  H J Okano; R B Darnell
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

7.  A T-cell receptor associated with naturally occurring human tumor immunity.

Authors:  Bianca D Santomasso; Wendy K Roberts; Ashby Thomas; Travis Williams; Nathalie E Blachère; Mark E Dudley; Alan N Houghton; Jerome B Posner; Robert B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

8.  CDR2 antigen and Yo antibodies.

Authors:  Cecilie Totland; Nina K Aarskog; Tilo W Eichler; Mette Haugen; Jane K Nøstbakken; Sissel E Monstad; Helga B Salvesen; Sverre Mørk; Bjørn I Haukanes; Christian A Vedeler
Journal:  Cancer Immunol Immunother       Date:  2010-11-16       Impact factor: 6.968

Review 9.  Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

Authors:  Meleeneh Kazarian; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2011-03-30       Impact factor: 27.401

Review 10.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.